c-Myc
Os inibidores de c-Myc têm como alvo a proteína c-Myc, um fator de transcrição que desempenha um papel crucial no crescimento celular, proliferação e apoptose. c-Myc regula a expressão de numerosos genes envolvidos no ciclo celular e é frequentemente superexpresso em vários tipos de câncer, levando a uma proliferação celular descontrolada e ao crescimento tumoral. Inibir o c-Myc pode interromper esses processos, induzindo a parada do ciclo celular e a apoptose em células cancerígenas. Os inibidores de c-Myc são ferramentas importantes na pesquisa do câncer e no desenvolvimento terapêutico. Na CymitQuimica, oferecemos uma ampla gama de inibidores de c-Myc de alta qualidade para apoiar sua pesquisa em oncologia, regulação do ciclo celular e controle transcricional.
Foram encontrados 83 produtos para "c-Myc".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
Ceramides Mixture
CAS:Ceramides Mixture: endogenous, regulates cell cycle, growth, and telomerase activity, with hydroxy/non-hydroxy fatty acids.Fórmula:C36H71NO4Pureza:98%Cor e Forma:White SolidPeso molecular:581.9532FIDAS-5
CAS:FIDAS-5 is an orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. Cost-effective and quality-assured.Fórmula:C15H13ClFNPureza:98.3% - 99.17%Cor e Forma:SolidPeso molecular:261.722FIDAS-3
CAS:FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activitiesFórmula:C16H15F2NPureza:97.75%Cor e Forma:SolidPeso molecular:259.2938Saxagliptin hydrate
CAS:Saxagliptin hydrate (Onglyza hydrate) is a selective and reversible DPP4 inhibitor (IC50: 26 nM; Ki: 1.3 nM).Fórmula:C18H27N3O3Pureza:99.52%Cor e Forma:SolidPeso molecular:333.4253MYCi361
CAS:MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).Fórmula:C26H16ClF9N2O2Pureza:99.52%Cor e Forma:SolidPeso molecular:594.856MYCi975
CAS:MYCi975 (NUCC-0200975) is an orally active inhibitor of MYC.Fórmula:C25H16Cl2F6N2O2Pureza:99.3% - 99.82%Cor e Forma:SolidPeso molecular:561.303MYCMI-6
CAS:MYCMI-6 inhibits MYC:MAX, reduces tumor growth, triggers apoptosis, minimal side effects.Fórmula:C20H19N7OPureza:99.23%Cor e Forma:Red SolidPeso molecular:373.4112Eragidomide
CAS:Eragidomide (Cereblon modulator 1) is a CRBN E3 ligase modulator, specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex.Fórmula:C22H18ClF2N3O4Pureza:99.13% - 99.63%Cor e Forma:White SolidPeso molecular:461.85APTO-253
CAS:APTO-253 (LOR-253) inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells.Fórmula:C22H14FN5Pureza:98.73%Cor e Forma:Yellow SolidPeso molecular:367.3785KJ Pyr 9
CAS:KJ Pyr 9 is an MYC inhibitor (Kd: 6.5 nM in vitro assay).Fórmula:C22H15N3O4Pureza:98% - 99.56%Cor e Forma:SolidPeso molecular:385.37PROTAC LZK-IN-1
CAS:PROTAC LZK-IN-1 (Compound 21A) is a PROTAC molecule that targets the degradation of LZK (leucine zipper kinase, encoded by MAP3K13). At a concentration of 10 μM, PROTAC LZK-IN-1 facilitates the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. This compound is applicable in anticancer research.Fórmula:C51H64F2N10O5SCor e Forma:SolidPeso molecular:967.18c-Myc inhibitor 10
CAS:c-Myc inhibitor 10 enhances cell potency with improved permeability from methylated morpholine nitrogen.Fórmula:C28H38N6O3Cor e Forma:SolidPeso molecular:506.64Anticancer agent 263
Anticanceragent 263 (compound 7) is an effective anticancer agent. It binds with the G-quadruplex DNA (G4) sequence 22-mer Pu22 (a c-Myc DNA analog). As a structural modulator, Anticanceragent 263 significantly enhances the formation of protein α-helices and has the capacity to form a supramolecular network. Furthermore, Anticanceragent 263 exhibits no cytotoxicity.Fórmula:C13H20N2O6Cor e Forma:SolidPeso molecular:300.308PROTAC MTP3 degrade-1
PROTACMTP3 degrade-1 is a PROTAC degrader for MYC.Fórmula:C44H38N6O8Cor e Forma:SolidPeso molecular:778.27511H122
H122 is a TEADPROTAC degrader effective in degrading TEAD1 with a DC50 of 3 nM, and it shows strong affinity for TEAD2, TEAD3, and TEAD4 with Ki values of 2.0, 3.6, and 1.6 nM, respectively. H122 also downregulates Myc expression and inhibits the growth of MSTO-211H and NCI-H226 cells, with IC50 values of 21.3 nM and 0.6 nM, respectively, demonstrating antitumor activity in mouse models. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligaseCereblon)Fórmula:C45H45ClFN5O8Cor e Forma:SolidPeso molecular:838.319VGN50
VGN50 is a bioactive molecule that mimics the function of K-Rta, capable of downregulating MYC-mediated gene transcription. VGN50 exhibits antitumor activity.Fórmula:C121H218N46O32Peso molecular:2827.68453RA-V
CAS:RA-V is a natural product that can be used as a reference standard.Fórmula:C40H48N6O9Cor e Forma:SolidPeso molecular:756.85c-Myc inhibitor 13
c-Myc inhibitor13 (compound A6) is an inhibitor of c-MYC transcription. It selectively stabilizes c-MYCG4 and inhibits G4-related c-MYC transcription.Fórmula:C30H39N9OCor e Forma:SolidPeso molecular:541.32776Methylcarbamyl PAF C-8
Methylcarbamyl PAF C-8 is resistant to degradation by PAF-AH and has a half-life of over 100 minutes in platelet-poor plasma, exhibiting platelet aggregation activity. In NRK-49 cells overexpressing PAF receptor, it induces the expression of c-myc, c-fos, and activates mitogen-activated protein kinase (MAPK). Furthermore, Methylcarbamyl PAF C-8 can induce G1 phase cell cycle arrest. This compound shows potential for research in cardiovascular and anti-cancer applications.Cor e Forma:Odour SolidMYC-IN-2
CAS:MYC-IN-2 is a protein-protein inhibitor targeting the MYC protein, designed for use in cancer research.Fórmula:C25H17N3O2SCor e Forma:SolidPeso molecular:423.49
